10x Genomics (TXG) | News Based Sentiment Analysis

• On August 7, 2025, 10x Genomics reported a surprisingly strong second quarter, with earnings per share coming in at $0.28 – significantly beating the expected loss of $0.35. Revenue also exceeded expectations, reaching $172.91 million compared to the anticipated $139.36 million, representing a 12.9% increase year-over-year. This positive performance suggests strong demand for their spatial biology solutions.
• Following the strong Q2 results, the company issued Q3 2025 revenue guidance in the range of $140 million to $144 million, but noted that approximately $4 million of revenue was pulled forward from Q3 to Q2 in China due to potential tariff changes. While the guidance is positive, investors should be aware of this timing impact.
• The company strategically expanded its capabilities with the acquisition of Scale Biosciences on August 7, 2025, though the immediate revenue impact is expected to be minimal. The long-term goal is to integrate Scale Biosciences’ technologies into 10x Genomics’ broader portfolio, enhancing their offerings.
• Analyst sentiment surrounding 10x Genomics is mixed, with price target adjustments occurring between August 8, 2025, and September 4, 2025. Barclays raised its price target to $15.00, while Morgan Stanley reduced theirs to $17.00, illustrating differing views on the company’s future potential. Despite the mixed signals, Wall Street Zen upgraded the stock to a “buy” rating.
• Insider selling activity occurred on August 22, 2025, with CEO Serge Saxonov and CFO Adam Taich selling shares. Saxonov sold 9,348 shares for $128,908.92 (a 0.98% decrease in ownership), and Taich sold 22,315 shares for $307,723.85 (a 6.73% decrease in position). This insider selling could raise concerns among some investors.
• Institutional investors continued to show confidence in 10x Genomics, with Nuveen LLC, Trexquant Investment LP, and Russell Investments Group Ltd. all increasing their stakes in September 1, 2025. Trexquant Investment LP notably increased its stake by 91.8%, now holding approximately $9.95 million worth of shares. Institutional investors collectively own 84.68% of the company.
• On August 19, 2025, 10x Genomics launched Xenium Protein, a new product that advances spatial biology by enabling simultaneous RNA and protein analysis within the same cell. This innovation demonstrates the company’s commitment to cutting-edge technology and expanding its capabilities in the rapidly evolving field of spatial biology.

The Investment Story: 10x Genomics delivered a strong Q2 performance and continues to innovate with new product launches like Xenium Protein, but mixed analyst sentiment and insider selling create a nuanced investment picture. The acquisition of Scale Biosciences signals a strategic focus on portfolio expansion.

What It Means for Investors: The company’s strong financial results and innovative products suggest continued growth potential, but investors should monitor analyst ratings, insider activity, and the integration of Scale Biosciences. The pulled-forward revenue from China is a short-term factor to consider.

Looking Ahead: Investors should watch for updates on the integration of Scale Biosciences, further analyst commentary, and the impact of the $4 million revenue shift on Q3 results. Continued monitoring of insider trading activity will also be important.

The Bottom Line: 10x Genomics is a promising company in a growing field, but the mixed signals from analysts and insiders suggest a cautious approach is warranted. The strong Q2 results and innovative product pipeline provide a solid foundation, but investors should carefully weigh the risks and opportunities.